CPT® Code 86829

Official Description

Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, Flow cytometry); qualitative assessment of the presence or absence of antibody(ies) to HLA Class I or Class II HLA antigens

Common Language Description

The human leukocyte antigen (HLA) system is a critical component of the major histocompatibility complex (MHC), which plays a vital role in the immune system's ability to recognize self from non-self. This system is essential for the identification of specific characteristics of an individual's cells and tissues, thereby enabling the body to defend against foreign substances, including microorganisms and non-self cells and tissues. The HLA system is divided into two main classes: Class I and Class II. The CPT® Code 86829 pertains to the qualitative assessment of antibodies to HLA antigens, specifically focusing on the presence or absence of these antibodies against HLA Class I or Class II antigens. This assessment is crucial in various clinical scenarios, particularly in the context of organ transplantation, where the presence of HLA antibodies can significantly influence the risk of immunological responses. The testing methodology often involves solid phase assays, such as enzyme-linked immunosorbent assay (ELISA), which utilizes fluorescent beads coated with HLA molecules. These beads can be analyzed using flow cytometry or Luminex instrumentation to detect the antibodies. The qualitative nature of this test allows healthcare providers to determine whether a patient has developed antibodies against HLA antigens, which is particularly important for patients previously identified with Class I or Class II HLA antibodies.

1. Indications

The qualitative assessment of antibodies to human leukocyte antigens (HLA) is performed under specific clinical circumstances. The following indications are explicitly associated with the use of CPT® Code 86829:

Organ Transplantation: This test is primarily indicated for patients undergoing evaluation for organ transplantation, as the presence of HLA antibodies can predict the risk of immunological responses that may lead to transplant rejection.
Follow-Up Testing: It is often utilized as a follow-up for patients who have previously been classified with Class I or Class II HLA antibodies, to monitor changes in antibody status.

2. Procedure

The procedure for conducting the qualitative assessment of antibodies to HLA involves several key steps, which are outlined below:

Sample Collection: A blood sample is collected from the patient, which will be used for the analysis of HLA antibodies. Proper collection techniques must be followed to ensure sample integrity.
Preparation of Solid Phase Assay: The laboratory prepares a solid phase assay, typically using microspheres or beads that are coated with specific HLA antigens. This preparation is crucial for the subsequent detection of antibodies.
Incubation: The patient’s serum is added to the solid phase assay, allowing any antibodies present in the serum to bind to the HLA antigens on the beads. This incubation period is essential for the formation of antibody-antigen complexes.
Detection: After incubation, the assay is subjected to detection methods such as enzyme-linked immunosorbent assay (ELISA) or flow cytometry. These methods enable the identification of bound antibodies, indicating the presence or absence of HLA antibodies.
Data Analysis: The results are analyzed to determine whether antibodies to HLA Class I or Class II antigens are present. This qualitative assessment provides critical information for clinical decision-making.

3. Post-Procedure

Post-procedure care for patients undergoing the HLA antibody assessment typically involves monitoring for any immediate reactions to the blood draw. Patients may be advised to follow up with their healthcare provider to discuss the results of the test. The interpretation of the results is crucial, as it can influence further management, particularly in the context of organ transplantation. If antibodies are detected, additional testing or interventions may be necessary to address potential immunological risks.

Short Descr	HLA CLASS I/II ANTIBODY QUAL
Medium Descr	ANTIBODY HLA CLASS I OR CLASS II ANTIGENS QUAL
Long Descr	Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, Flow cytometry); qualitative assessment of the presence or absence of antibody(ies) to HLA Class I or Class II HLA antigens
Status Code	Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	09 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
CLIA Waived (QW)	No
APC Status Indicator	Conditionally packaged laboratory tests
Type of Service (TOS)	5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS)	T1H - Lab tests - other (non-Medicare fee schedule)
MUE	1
CCS Clinical Classification	235 - Other Laboratory

Professional component: certain procedures are a combination of a physician or other qualified health care professional component and a technical component. when the physician or other qualified health care professional component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number.